



Gerstner Sloan Kettering
Graduate School of Biomedical Sciences

[Welcome to GSK](#)

[The Andrew Koff Lab](#)

[Admissions](#)

Marta Kovatcheva, PhD

[Cancer Biology](#)

Graduate Student

[Cancer Engineering](#)

[Research](#)

[Alumni](#)



Lab Phone

212-639-2354

Email

KovatchM@sloankettering.edu

Dissertation

[New roles for old proteins: MDM2 and ATRX drive the transition from quiescence to senescence \(2017\)](#)

Mentor

[Andrew Koff, PhD](#)

Start Year

2010

End Year

2017

Education

University of Toronto

Fellowships

[Grayer Fellowship](#) (2012-2013)

[Natural Sciences and Engineering Research Council of Canada Postgraduate Scholarship](#) (2011-2012)

Publications

[Kovatcheva M, Klein ME, Tap WD, Koff A. \(2017\) Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors. *Mol Cell Oncol*. 5, e1384882. PMID: PMC5791849. \[Available on 2018-11-07\]](#)

[Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. \(2018\) CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. *Cancer Cell*. \[Epub ahead of print\]](#)

[Kovatcheva M, Liao W, Klein ME, Robine N, Geiger H, Crago AM, Dickson MA, Tap WD, Singer S, Koff A. \(2017\) ATRX is a regulator of therapy induced senescence in human cells. *Nat Commun*. 8, 386. PMID: PMC5577318](#)

[Kovatcheva M, Liu DD, Dickson MA, Klein ME, O'Connor R, Wilder FO, Socci ND, Tap WD, Schwartz GK, Singer S, Crago AM, Koff A. \(2015\) MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. *Oncotarget*. 6, 8226-43. PMID: PMC4480747.](#)

[View a full listing of Marta Kovatcheva's journal articles.](#)

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility Statement](#)

[Privacy policy](#)

[Public notices](#)

